Novel Use of Hydroxyurea in an African Region With Malaria: Protocol for a Randomized Controlled Clinical Trial

BACKGROUND: Sickle cell anemia (SCA), one of most prevalent monogenic diseases worldwide, is caused by a glutamic acid to valine substitution on the beta globin protein of hemoglobin, which leads to hemolytic anemia. Hydroxyurea, the only disease-modifying therapy approved by the Food and Drug Admin...

Descripción completa

Detalles Bibliográficos
Autores principales: Anyanwu, Juliana N, Williams, Olatundun, Sautter, Casey L, Kasirye, Phillip, Hume, Heather, Opoka, Robert O, Latham, Teresa, Ndugwa, Christopher, Ware, Russell E, John, Chandy C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JMIR Publications 2016
Materias:
Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4937184/
https://www.ncbi.nlm.nih.gov/pubmed/27339303
http://dx.doi.org/10.2196/resprot.5599

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4937184/
https://www.ncbi.nlm.nih.gov/pubmed/27339303
http://dx.doi.org/10.2196/resprot.5599

Ejemplares similares